LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Impax Laboratories, Inc. (“Impax” or the “Company”) (Nasdaq: IPXL) concerning possible violations of federal securities laws between February 25, 2014 and November 3, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the January 9, 2017 lead plaintiff motion deadline.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The complaint alleges that during the Class Period, Impax made false and/ misleading statements and/or failed to disclose: that the Company was engaged in conduct that would trigger investigations of possible collusion of generic drug pricing by the antitrust division of the U.S. Department of Justice (“DOJ”) and the Connecticut Attorney General; that the DOJ investigation and the underlying conduct would likely result in criminal charges against Impax for collusion of generic drug pricing; that the Company lacked effective internal controls over financial reporting; and that as a result of the above, Impax’s public statements were materially false and misleading at all relevant times.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.